[ad_1]
The CEO of AstraZeneca, a multinational pharmaceutical company based in London, United Kingdom, was confident in the success of the new vaccine against coronavirus infection (Corona 19) developed with the University of Oxford on the 27th at local time.
Pascal Sorio (61), executive editor of the Daily The Times, told The Times’ Sunday Times that, like other competitors, “I think we have discovered a successful formula that can benefit from two doses of the vaccine.” In an interview conducted for burns while at home in Sydney, Australia, he said: “It is 100% preventable from COVID-19 infection which is severe enough to have to be hospitalized.”
The COVID-19 vaccine developed by AstraZeneca and the University of Oxford showed different immunity effects depending on the dose as a result of an interim analysis of the phase 3 clinical trial. When the full dose of the vaccine was administered twice, the rate of Prevention was only 62.1%, but when the first half dose was administered and the second full dose was administered, the prevention rate increased to 90.0%.
The average prevention rate is 70.4%, which is less effective than the vaccine developed by Pfizer, a US pharmaceutical company, and Bioentech, Germany (95%), and a vaccine developed by the US pharmaceutical company Modena (94, 5%). CEO Sorio admitted he was “surprised” when he first discovered that the immune effects were different depending on the dose of the vaccine, and confessed: “I knew for sure that people might be a little disappointed.”
“Of course, I would have liked the results to be simpler, but the overall assessment was positive because it met the standards set by regulatory authorities around the world,” he added. When AstraZeneca and the University of Oxford announced their interim clinical results last month, criticism emerged over the difference in efficacy based on dosage, and the share price fell 3.8%.
When calculating all cases, the average prevention rate is 70.4%. Taking into account that the Pfizer vaccine, an American pharmaceutical company, has a prevention rate of 95% and 94.5%, the effectiveness is very low. CEO Sorio said AstraZeneca and the University of Oxford are currently working on a new version of the vaccine. Hopefully it is not necessary, but it is because preparations like the mutant corona 19 virus that appeared in South Africa are necessary.
On the 21st, AstraZeneca and the University of Oxford applied for the emergency use of the Corona 19 vaccine manufactured by both companies to the UK Medicines and Healthcare Products Regulatory Authority (MHRA). The Daily Telegraph reported on the same day that MHRA, which continues to deliberate over the Christmas holidays, may announce whether the vaccine is approved for emergency use starting on the 27th.
UK health officials said: “MHRA is reviewing the final data from a phase 3 clinical trial to ensure that the AstraZeneca vaccine meets strict standards for quality, safety and efficacy. We have time to ensure that MHRA can do what It is important”. And he waits for his advice. “
Recently, in the UK, a Corona 19 variant is being rolled out, which is 70% more powerful than the existing Corona 19, and public opinion is spreading that the speed of vaccine distribution should be increased. The Korean government has also insured 10 million AstraZeneca vaccines. La Casa Azul predicted that vaccinations for the elderly and medical personnel will begin in February next year. Compared to other vaccines, the AstraZeneca-Oxford vaccine is cheaper and can be stored in a general refrigerator, so the transport process is not difficult.
Reporter Geum-ju Cheon [email protected]
GoodNews paper ⓒ Kookmin Ilbo (www.kmib.co.kr), unauthorized reproduction, compilation, redistribution prohibited
[ad_2]
